Skip to main content
. 2022 Feb 22;13:828319. doi: 10.3389/fimmu.2022.828319

Figure 8.

Figure 8

BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy through multiple mechanisms of action. (A) Rejuvenation of T and NK cells. (B) Preferential Treg depletion through ADCC/ADCP. (C) NK activation through TIGIT binding and FcγR crosslinking. (D) Myeloid cell activation through FcγR crosslinking. (E) Removal of TIGIT molecules from T cell and NK cell surfaces.